Lateral Cord Stimulation as a New Treatment for Refractory Spastic Cerebral Palsy
Launched by JUAN CARLOS M. ANDREANI MD · Jul 21, 2014
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into a new treatment for adults and teens with spastic cerebral palsy, a condition that causes muscle stiffness and difficulty with movement. The researchers want to see if a technique called Lateral Cord Stimulation (LCS), which involves using electrical signals to stimulate the spinal cord, can help reduce muscle tightness and improve movement by activating certain areas of the brain.
To participate in this study, individuals must be at least 16 years old and have a stable form of spastic cerebral palsy that mainly affects one side of their body. They should also have some speech difficulties but no serious mental health issues. Participants can expect to undergo evaluations to see if they qualify and will be closely monitored throughout the trial. It's important to note that certain health conditions, like severe heart or lung problems, may exclude someone from participating. This trial is not yet recruiting participants, but it aims to provide new hope for those struggling with spasticity related to cerebral palsy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged sixteen or older
- • Spastic Cerebral Palsy with stable condition
- • Motor disability unilateral or predominantly unilateral.
- • Troubles of speech clinically evident.
- • Normal or Slightly sub-normal I.Q
- • No psychiatric disorders.
- Exclusion Criteria:
- • Severe cardiac or respiratory troubles
- • Fixed abnormal postures (except if previously corrected by orthopedic surgery)
- • Chronic recurrent bronchial or pulmonary infections
- • Chronic recurrent urinary infections
- • Severe osteoporosis on affected limbs
- • Chronic skin ulcerations.
About Juan Carlos M. Andreani Md
Dr. Juan Carlos M. Andreani, MD, is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical medicine and a focus on innovative therapeutic approaches, Dr. Andreani leads trials that explore novel treatments across various medical fields. His dedication to rigorous scientific methodology and ethical standards ensures the integrity of research initiatives, fostering collaboration with healthcare professionals and institutions. Through his leadership, Dr. Andreani aims to contribute to the body of evidence that informs best practices in patient care and enhances the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Plata, Buenos Aires, Argentina
Magdeburg, , Germany
Patients applied
Trial Officials
Juan Carlos Andreani, MD
Study Director
Sociedad Argentina de Neuromodulación
Werner Braunsdorf, MD
Principal Investigator
Klinik von Magdeburg - Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials